Xiaole Shirley Liu, a leader in US HealthTech, is the Co-founder and CEO of GV20 Therapeutics, a clinical-stage immuno-oncology company. Liu drives GV20’s mission to revolutionize cancer treatment using AI and genomics, developing innovative antibody therapeutics. Their lead program, GV20-0251, an AI-designed antibody, reached IND in just three years. Previously a professor at Harvard and DFCI, Liu has published over 270 papers and mentored numerous trainees.
666 3rd Ave, 6th Floor, New York, NY 10017